The Food and Drug Administration is studying whether legal cannabis is safe in food or supplements and plans to make recommendations for how to regulate the growing number of cannabis-derived products in the coming months, The Wall Street Journal’s Liz Essley Whyte reports, citing agency officials. "Given what we know about the safety of CBD so far, it raises concerns for FDA about whether these existing regulatory pathways for food and dietary supplements are appropriate for this substance," said FDA Principal Deputy Commissioner Janet Woodcock, who has led the agency’s efforts looking at cannabis regulation. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), India Globalization Capital (IGC), Tilray (TLRY), Trees Corporation (CANN), Trulieve Cannabis (TCNNF) and Zynerba (ZYNE).Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACB:
- Rising High: Exclusive talk with staffing firm CannabizTeam
- Largest borrow rate increases among liquid names
- Rising High: Exclusive talk with market research firm Brightfield Group
- Here’s What You Missed in Cannabis This Week
- Defense bill with marijuana reform attached is delayed, Marijuana Moment says